Our results demonstrated that patients with NSCLC who developed any irAE after anti-PD-1 treatment showed a 50% reduction in the risks of death and disease progression compared to those without any AEs related to ICIs. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.